Expert Opin Pharmacother. 2009 Sep;10(13):2161-9.

Conivaptan: promise of treatment in heart failure.

Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH.

Source

Albert Einstein Medical Center, Cardiology, 5501 Old York Road, Philadelphia, PA 19141, USA.

Abstract

Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HF. Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.

PMID:: 19663609; [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Heart Failure - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. [Clin Ther. 2009]
Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL, Stalker D, Keirns J. Clin Ther. 2009 Jul; 31(7):1542-50.
Review Conivaptan: new treatment for hyponatremia. [Am J Health Syst Pharm. 2007]
Review Conivaptan: new treatment for hyponatremia.
Walter KA. Am J Health Syst Pharm. 2007 Jul 1; 64(13):1385-95.
Review Vasopressin-receptor antagonists in heart failure. [Am J Health Syst Pharm. 2008]
Review Vasopressin-receptor antagonists in heart failure.
Schweiger TA, Zdanowicz MM. Am J Health Syst Pharm. 2008 May 1; 65(9):807-17.
Review Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. [Drug Discov Today. 2010]
Review Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Komai Y, Thandavarayan RA, Sukumaran V, Watanabe K. Drug Discov Today. 2010 Oct; 15(19-20):826-41. Epub 2010 Aug 11.
Review Therapeutic potential of vasopressin receptor antagonists. [Drugs. 2007]
Review Therapeutic potential of vasopressin receptor antagonists.
Ali F, Guglin M, Vaitkevicius P, Ghali JK. Drugs. 2007; 67(6):847-58.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Conivaptan: promise of treatment in heart failure.
Conivaptan: promise of treatment in heart failure.
Expert Opin Pharmacother. 2009 Sep ;10(13):2161-9.

PubMed
Conference scene: nanotechnology and medicine: the next big thing is really smal...
Conference scene: nanotechnology and medicine: the next big thing is really small.
Nanomedicine (Lond). 2009 Aug ;4(6):619-21.

PubMed
The effects of corticosteroids on bone growth and bone density.
The effects of corticosteroids on bone growth and bone density.
Ann Allergy Asthma Immunol. 2009 Jul ;103(1):3-11; quiz 11-3, 50.

PubMed
Update on physical activity including special needs populations.
Update on physical activity including special needs populations.
Curr Opin Pediatr. 2009 Apr ;21(2):262-268.

PubMed
Air pollution and childhood asthma: recent advances and future directions.
Air pollution and childhood asthma: recent advances and future directions.
Curr Opin Pediatr. 2009 Apr ;21(2):235-42.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: